CDK7-IN-20

• Description :

  CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research[1].

• UNSPSC :

  12352005

• Target :

  CDK; GSK-3

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/cdk7-in-20.html

• Solubility :

  10 mM in DMSO

• Smiles :

  C=CC(NC1=CC=C(C=C1)C(NC2=NNC3=C2C=C(C=C3)C4=CC(NC[C@H](C5=CC=CC=C5)O)=CN=C4)=O)=O

• Molecular Formula :

  C30H26N6O3

• Molecular Weight :

  518.57

• References & Citations :

  [1]Bowen Yang, et al. Discovery of Novel N- (5- (Pyridin-3-yl) -1 H-indazol-3-yl) benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. J Med Chem. 2022 Nov 17.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK1; CDK12; CDK2; CDK3; CDK5; CDK6; CDK7; CDK9; GSK-3β

• CAS Number :

  [3034210-97-1]